GlassScriptPhysician profile
James Alan Senft
NPI 1003909169
$597.93
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $78.17 · 2021: $312.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $280.52 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $114.96 | 2019-2020 | |
| Radius Health, INC. | $40.00 | 2019 | |
| Amgen INC. | $38.45 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $29.07 | 2021 | |
| Pfizer INC. | $27.93 | 2019-2021 | |
| Glaxosmithkline, LLC. | $15.48 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.74 | 2019 | |
| Allergan, INC. | $12.78 | 2019 | |
| Merck Sharp & Dohme LLC | $12.31 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.69 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Senft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.